Regeneron Pharmaceuticals Inc (REGN) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.

Total Revenue Chart for Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc (REGN) revenue for FY2025 was USD 14.3B, a 1.0% change from FY2024. Regeneron Pharmaceuticals Inc's revenue grew from USD 5.0M in 1990 to USD 14.3B in 2025 (286758.0% over 35 years). Earnings per share grew from USD 0.74 in 2004 to USD 38.22 in 2022 (5049.1%). Revenue compound annual growth rate: 5-year CAGR of 11.0%, 10-year CAGR of 13.3%, 20-year CAGR of 30.9%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$79.49B
Implied Share Price
$785.98
Enterprise Value
$73.03B
Revenue (TTM)
$15.53B
EBITDA
$4.70B
Profit Margin
27.87%
Trailing P/E
19.01
Forward P/E
16.61
Price/Book (MRQ)
2.47
Price/Sales (TTM)
5.12
EV/EBITDA
12.70
EV/Revenue
4.70
Dividend Yield
0.47%
Book Value
$316.11
Free Cash Flow (FY2025)
$4.08B
Free Cash Flow Yield
5.13%

Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.